Inovio Pharmaceuticals Faces Investor Deadline

Law firm Rosen urges shareholders to take action against the biotech company.

Mar. 31, 2026 at 4:22am

Got story updates? Submit your updates here. ›

Inovio Pharmaceuticals, a biotechnology company, is facing a deadline set by law firm Rosen for investors to take action. The firm is encouraging Inovio shareholders to join a class action lawsuit against the company, citing concerns over its business practices and financial performance.

Why it matters

Inovio is a prominent player in the pharmaceutical industry, and any legal issues or shareholder unrest could have significant implications for the company's future. This deadline represents an escalation of tensions between Inovio and its investors, potentially signaling deeper problems within the organization.

The details

The Rosen law firm has set a deadline for Inovio shareholders to join a class action lawsuit against the company. The lawsuit alleges that Inovio has made misleading statements about its business and financial outlook, potentially deceiving investors. The firm is urging shareholders to take action before the deadline to protect their interests.

  • The deadline set by Rosen law firm is March 30, 2026.

The players

Inovio Pharmaceuticals Inc.

A biotechnology company that develops DNA medicines to treat and prevent infectious diseases, cancer, and other diseases.

Rosen Law Firm

A law firm that specializes in representing investors in class action lawsuits against public companies.

Got photos? Submit your photos here. ›

What’s next

The Rosen law firm will continue to pursue the class action lawsuit against Inovio on behalf of its shareholders.

The takeaway

This deadline highlights the ongoing tensions between Inovio and its investors, which could have significant implications for the company's future if the legal issues are not resolved. Shareholders will need to carefully consider their options before the deadline to protect their investments.